# Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

> **NCT00994318** · PHASE3 · COMPLETED · sponsor: **Vifor Pharma** · enrollment: 626 (actual)

## Conditions studied

- Iron Deficiency Anaemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** FCM (Ferric carboxymaltose) high ferritin target
- **DRUG:** FCM (Ferric carboxymaltose) low ferritin target
- **DRUG:** Oral Iron (Ferrous sulphate)

## Key facts

- **NCT ID:** NCT00994318
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-02
- **Final completion:** 2014-02
- **Target enrollment:** 626 (ACTUAL)
- **Last updated:** 2014-05-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994318, "Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00994318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*